Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective

doi:10.1177/0300891620985309

HFCAS OpenIR

	Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective
	Tong, Ying-hui 1,2; Ding, Hai-ying 1,2; Xin, Wen-xiu 1,2; Zhong, Li-ke 1,2; Xu, Gao-qi 1,2; Zhang, Bo 2,3; Yang, Guo-nong 1,2; Fang, Luo 1,2
	2021-01-29
发表期刊	TUMORI JOURNAL
ISSN	0300-8916
通讯作者	Yang, Guo-nong(yanggn@zjcc.org.cn) ; Fang, Luo(Fangluo@zjcc.org.cn)
摘要	Introduction: Results from the CASPIAN trial (Durvalumab +/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer) trial demonstrated the clinical benefit of durvalumab plus etoposide-platinum (EP) chemotherapy as first-line treatment for patients with extensive stage small-cell lung cancer (ES-SCLC). However, considering the high price of durvalumab, it is unclear whether addition of durvalumab to EP chemotherapy has economic value compared with EP alone. In this study, we aimed to evaluate the cost-effectiveness of durvalumab plus EP chemotherapy as a first-line treatment for patients with ES-SCLC. Methods: A Markov model comprising three health states (stable, progressive, and dead) was developed to simulate the process of small-cell lung cancer. Utility and costs were obtained from published resources. Health outcomes were derived from the CASPIAN trial. Costs were calculated based on the standard medical fees in Zhejiang Province from Chinese patients' perspective. Utility values were obtained from published data. One-way and probabilistic sensitivity analyses were applied to verify model robustness. Results The addition of durvalumab to EP chemotherapy costs more than $32,220, with a gain of 0.14 quality-adjusted life years (QALYs) compared with EP alone. The incremental cost-effective ratio was $230,142.9 per QALY, which exceeds the willingness to pay threshold of $28,527 per QALY. In the sensitivity analysis, the utility values for the progressive state, costs of durvalumab and EP chemotherapy, and costs for the progressive state were considered to be the three most sensitive factors in the model. Conclusion: The addition of durvalumab to EP chemotherapy is not a cost-effective strategy in the first-line therapy of ES-SCLC from the Chinese payers' perspective.
关键词	Cost-effectiveness durvalumab etoposide plus platinum chemotherapy first-line treatment SCLC
DOI	10.1177/0300891620985309
收录类别	SCI
语种	英语
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000680429700001
出版者	SAGE PUBLICATIONS LTD
引用统计	被引频次：7[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/123162
专题	中国科学院合肥物质科学研究院
通讯作者	Yang, Guo-nong; Fang, Luo
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Dept Pharm, Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Zhejiang, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Dept Integrated Chinese & Western Med, Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Tong, Ying-hui,Ding, Hai-ying,Xin, Wen-xiu,et al. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective[J]. TUMORI JOURNAL,2021.
APA	Tong, Ying-hui.,Ding, Hai-ying.,Xin, Wen-xiu.,Zhong, Li-ke.,Xu, Gao-qi.,...&Fang, Luo.(2021).Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.TUMORI JOURNAL.
MLA	Tong, Ying-hui,et al."Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective".TUMORI JOURNAL (2021).